Aerie Pharmaceuticals commences Phase 2 clinical trial of AR-1105
Category: #health  By Mateen Dalal  Date: 2019-03-19
  • share
  • Twitter
  • Facebook
  • LinkedIn

Aerie Pharmaceuticals commences Phase 2 clinical trial of AR-1105

AR-1105 is an intravitreal, fully bio-erodible PRINT-manufactured implant that releases steroid dexamethasone.

Aerie Pharmaceuticals, an ophthalmic pharmaceutical company, has reportedly initiated the Phase 2 clinical trial evaluating AR-1105 for investigation of its dexamethasone intravitreal implant in patients suffering from macular edema caused by retinal vein occlusion (RVO).

Up to 45 patients will be enrolled for this Phase 2 study and trial will be conducted at approximately 20 centers in United States. The primary endpoint of this study is safety, tolerability, and efficacy of AR-1105 dexamethasone intravitreal implant. The estimated date of completion is January 2020.

As per a press release by Aerie Pharmaceuticals, there will be two stages in this study. In first stage, up to 5 patients will be enrolled to receive CF-1 and in stage-2, up to 40 randomized patients will receive either CF-1 or CF-2. CF-2 delivers same dose of dexamethasone for a longer period. This study has been made available at www.clinicaltrials.gov.

Chairman and Chief Executive Officer, Vicente Anido, Jr., Ph.D., cited that they are building a concept study for AR-1105 and retina portfolio based on technology of DSM being developed with bio-erodible polymers and platform of PRINT manufacturing.

He further stated that they are expecting the trial to allow optimization of AR-1105 for achieving their objective in Phase 3 studies. They also have plans to file an investigational new drug, AR-13503 implant, which is a bio-erodible implant delivering Rho kinase/Protein kinase C inhibitor for treating wet-related macular degeneration and diabetic macular edema.

AR-1105 is an intravitreal, fully bio-erodible PRINT-manufactured implant that releases steroid dexamethasone. It is administered by a commonly used in-office treatment called Intravitreal Injection.

For the record, Aerie Pharmaceuticals is a clinical-stage, public pharmaceutical company, concentrated on discovery, development, and commercial aspects of first-in-class therapies for treating patients with eye diseases. Aerie's two lead product candidates are once-daily IOP-lowering therapies with novel mechanisms of action to treat patients with glaucoma or ocular hypertension.

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Air France-KLM & JAL make bids to purchase stake in Malaysia Airlines
Air France-KLM & JAL make bids to purchase stake in Malaysia Airlines
By Mateen Dalal

Air France–KLM S.A., one of the leading global air transport players, has reportedly made a proposal to invest in Malaysia Airlines and gain around 49 percent stake. Japan Airlines (JAL) is also looking to acquire a 25 percent stake in Mal...

Accenture opens innovation center in South Beach Road office
Accenture opens innovation center in South Beach Road office
By Mateen Dalal

Accenture, an Irish multinational professional services company, has recently opened a global innovation center within the Accenture’s office at South Beach Road, which is supported by EDB (Economic Development Board) in Singapore. It will pro...

Verrica unveils positive data from VP-102 study in molluscum treatment
Verrica unveils positive data from VP-102 study in molluscum treatment
By Mateen Dalal

Findings from the study are being produced at the 17th Annual Winter Clinical Dermatology Conference in Kohala Coast The data indicated a considerable increase in the percentage of patients with lesion clearance in VP-102 group Verrica Pharmaceu...